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Abstract
Background: Non-Hodgkin lymphomas are a heterogeneous group, which involve either B or T lymphocytes. The
most used treatment is a chemotherapy regimen, which includes cyclophosphamide, hydroxydaunorubicin, oncovin
and prednisone combined with rituximab - a monoclonal antibody specific for CD20 - an antigen expressed on B
lymphocyte membrane. Nonmelanoma skin cancers are the most common forms in patients who have lymphomas.
Case presentation: We reported the cases of two Caucasian men affected by non-Hodgkin disease, treated with
chemotherapy and rituximab. After treatment, they both presented superficial basal cell carcinoma and we prescribed
imiquimod 5 % cream. Unfortunately, the drug was not effective in either patient and the tumors were excised.
Conclusions: We speculated about the effect of rituximab on B lymphocytes, on a particular population of T cells and
on antigen-presenting dendritic cells that may have determined a lower expression of some surface antigens involved
in antigen presentation. These cells are the specific targets of imiquimod to promote skin cancer cells apoptosis. A lack
of action by imiquimod on skin cancer after treatment with rituximab is likely due to its transitory inhibitory effects on
lymphocytes and Langherans cells. Further studies could be useful to understand the mechanism behind the lack of
response.
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Background
Non-Hodgkin lymphomas (NHLs) are a heterogeneous
group, which involve either B or T lymphocytes. Their
causes may vary and include infectious agents, chemi-
cals, autoimmune and genetic diseases. Clinical presen-
tation consists in fever, night sweats, weight loss,
asthenia, pruritus and superficial nonpainful lymphaden-
opathy. The most used treatment is a chemotherapy
regimen, which includes cyclophosphamide, hydroxy-
daunorubicin, oncovin and prednisone (CHOP). This is
usually combined with rituximab (RTX), a monoclonal
antibody specific for CD20, an antigen expressed on B
lymphocyte membrane [1]. Nonmelanoma skin cancers
(NMSCs), including basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC), are common forms of
malignancy in the general population, and in immuno-
suppressed people in particular, especially in those with
a lymphoma [2]. They are more than 90 % of all skin
cancers and are mostly localized in the head-neck region
[3]. NHL patients are two times more predisposed to de-
velop second primary malignancies, with men at greater
risk compared to women [4]. NMSCs developed in these
patients were found to be more aggressive and at risk of
recurrence after Mohs microsurgery with respect to the
general population, due to the impairment of the
immune system during the hematologic disease and
chemotherapy [2]. Mohs microsurgery, or micrographic
surgery, was developed in the 1930s by F.E. Mohs and
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consists in microscopic examination of the tumor fol-
lowing its serial excision [5]. At present, patients prefer
a drug treatment for BCC like imiquimod as this ensures
a wider action on the field of cancerization through to
the activation of antigen-presenting cells (APCs) and
stimulation of T helper 1 (Th1) antitumoral cellular
immune response [6]. In this regard, imiquimod is the
most used and effective drug, especially on superficial
BCC, with a successful treatment in nearly 88 % of cases
[7, 8]. Imiquimod is an immunoresponse enhancer that
works by activating Toll-like receptor 7 (TLR-7). The
medicine is licensed in a cream form that patients use
for the treatment of external genital warts, superficial
BCCs, and actinic keratosis in adults [6, 9, 10]. Our
experience shows a comparable percentage of success of
the two, surgical and topical approaches (90–95 % vs.
85–90 %, respectively). Here we describe the cases of
two unrelated men affected by NHL and treated with
CHOP combined with RTX. About 6 months after RTX
suspension, they presented superficial BCC of the skin.
Case presentation
We present the cases of two Caucasian men in remission
for NHL, treated with CHOP for 6 cycles (for about 4
months). They both underwent autologous stem cell
transplantation after a carmustine, etoposide, cytarabine,
and melphalan/cyclophosphamide (BEAM/BEAC) con-
ditioning regimen. One of these patients was treated
with RTX at the same time as CHOP, while both used a
maintenance therapy for about 1 year with RTX after
transplantation. They were referred to our department
in their remission period and had not been using any
immunochemotherapy for about 6 months. Case 1 pa-
tient is a 62-year-old man with a superficial BCC of the
face (11 mm in diameter), while the case 2 patient, 47
years old, had two superficial BCCs on his back (8 and
13 mm in diameter). We prescribed imiquimod 5 %
cream since both patients wanted to avoid surgical pro-
cedures. We decided to start the treatment five times a
week for 8 weeks. At the end of this period, both
patients did not show any response to medication. At
follow-up, during the treatment, our patients did not
show any typical inflammatory response to the drug.
Consequently, the tumors had to be surgically removed.
The histopathological examination confirmed BCC in
both patients.
Discussion
Hematologic patients are at greater risk of developing
second primary malignancies, due to their immune im-
pairment, caused by the immunosuppressive factors they
produce, but also to the lymphoma treatment. According
to some studies, a history of chemotherapy is a risk fac-
tor for the development of BCC [2]. The gold standard
treatment is surgical excision, but in older people, pa-
tients with multiple lesions and transplanted patients,
the medical approach is to be preferred. The most used
topical therapies are imiquimod and 5-fluorouracil. Most
cases are treated with imiquimod rather than surgically,
as it has been shown that the drug acts also on the can-
cerization field, as demonstrated by the reduced risk of
subsequent BCC in treated patients [11]. Imiquimod is
an immune response modifier, which acts as a TLR-7
agonist. TLRs usually recognize pathogens and activate
the releasing of inflammatory cytokines. In fact, TLR-7
triggers the transcription factor NF-kappaB, promoting
the production of proinflammatory cytokines and other
inflammatory mediators. This function leads to the acti-
vation of APCs and stimulation of an important Th1 an-
titumoral cellular immune response. Moreover, at higher
concentrations, imiquimod causes a proapoptotic activ-
ity against tumor cells. This involves caspases activation
and apparently depends on Bcl-2 proteins. This family of
antiapoptotic proteins controls mitochondrial permeabil-
ity. Imiquimod induces a reduction of Bcl-2 protein ex-
pression and, consecutively, an increase of the apoptotic
index of the BCC cells [6]. Finally, it has been recently
demonstrated that imiquimod acts directly on BCC by
inhibiting Hedgehog signaling, given that this skin can-
cer is Hedgehog-driven [12]. The combination of all
these activities explains the antitumoral action of imiqui-
mod. In our two patients, previously treated with R-
CHOP, we observed a reduced efficacy of imiquimod.
This drug is used due to its effect on T cell activation,
on increasing natural killer (NK) cells and on APC func-
tions as well as against other tumors. Its efficacy has
been demonstrated on cutaneous lymphomas (mycosis
fungoides) [13]. Therefore, we speculate a likely effect of
previous treatment with RTX on T cells. RTX acts spe-
cifically on CD20, expressed on B lymphocyte membrane
with a transient effect on a particular population of T
cells. This subpopulation expresses CD20 surface anti-
gen, as well as CD3. They represent a pool of constitu-
tive activated T cells, which produce and release a high
quantity of proinflammatory cytokines [14]. Moreover,
we also studied and determined the effect of RTX on the
most important APCs, the dendritic cells (DCs). Apart
from morphology change, there was a lower expression
of some surface antigens (HLA-DR, CD80, CD83, CD86,
IL-12p70) involved in antigen presentation, stimulating
proliferation and inhibiting T cells apoptosis. Transform-
ing growth factor beta 1 (TGF-beta1) increased, thus
causing the inhibition of T cell action, preventing prolif-
eration of activated T lymphocytes/activation of quies-
cent helper or cytotoxic T cells and the secretion of
proinflammatory cytokines [especially interferon-gamma
(IFN-gamma) and interleukin-2 (IL-2)]. All these mecha-
nisms reflect a reduced ability to activate T cells by DCs
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[15]. We also saw a transient, dose-dependent T cell in-
activation after RTX administration. Their responsive-
ness to DCs reduced remarkably during treatment, as
shown by the higher risk of T cell-dependent infectious
diseases that then reduces a few months after the end of
the therapy [16]. We suppose that RTX is the cause of
the lack of response to imiquimod in these patients, be-
cause CHOP has been demonstrated to cause reversible
peripheral blood cytopenia. On the other hand, RTX re-
duces the function, as well the count of peripheral blood
and DCs. RTX most likely decreases the host immune
response making patients anergic toward topical im-
mune stimulation by imiquimod. Besides B cell deple-
tion, that could reflect the transient reduced activation
of T cells, RTX acts on T cells in different ways. Despite
its direct functioning on CD20+ T cells, this is only tran-
sient. The most likely mechanism of action of RTX
could be due to its action on DCs. In fact, patients with
an important reduction of T cell activation and function-
ing could develop typical T cell-dependent infectious
diseases.
Conclusions
Our clinical observation is useful for patients who
undergo specific targeted therapies such as RTX to con-
sider other therapeutic strategies in the management of
NMSC different from imiquimod.
Further studies are needed to determine the real
mechanism behind the lack of response to topical
imiquimod in patients previously treated with this
immunotherapy protocol.
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